Biomarin Pharmaceutical Inc [BMRN] stock is trading at $65.42, up 0.83%. An important factor to consider is whether the stock is rising or falling in short-term value. The BMRN shares have gain 4.57% over the last week, with a monthly amount drifted -6.42%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Biomarin Pharmaceutical Inc [NASDAQ: BMRN] stock has seen the most recent analyst activity on November 15, 2024, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $95. Previously, William Blair downgraded its rating to Mkt Perform on October 30, 2024. Bernstein upgraded its rating to a Outperform and increased its price target to $110 on August 20, 2024. Robert W. Baird downgraded its rating to a Neutral and reduced its price target to $72 on May 17, 2024. Evercore ISI started tracking with a Outperform rating for this stock on May 14, 2024, and assigned it a price target of $113. In a note dated November 15, 2023, Wells Fargo initiated an Overweight rating and provided a target price of $100 on this stock.
Biomarin Pharmaceutical Inc [BMRN] stock has fluctuated between $61.15 and $99.56 over the past year. Currently, Wall Street analysts expect the stock to reach $101.7 within the next 12 months. Biomarin Pharmaceutical Inc [NASDAQ: BMRN] shares were valued at $65.42 at the most recent close of the market. An investor can expect a potential return of 55.46% based on the average BMRN price forecast.
Analyzing the BMRN fundamentals
Biomarin Pharmaceutical Inc [NASDAQ:BMRN] reported sales of 2.75B for the trailing twelve months, which represents a growth of 26.69%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.11%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.06 and Total Capital is 0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 64.87 points at the first support level, and at 64.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 65.75, and for the 2nd resistance point, it is at 66.07.
Ratios To Look Out For
For context, Biomarin Pharmaceutical Inc’s Current Ratio is 4.27. On the other hand, the Quick Ratio is 2.62, and the Cash Ratio is 0.94. Considering the valuation of this stock, the price to sales ratio is 4.58, the price to book ratio is 2.30 and price to earnings (TTM) ratio is 39.39.
Transactions by insiders
Recent insider trading involved Guyer Charles Greg, EVP, Chief Technical Officer, that happened on Nov 12 ’24 when 5278.0 shares were sold. Officer, Guyer Charles Greg completed a deal on Nov 12 ’24 to buy 5278.0 shares. Meanwhile, GVP, Chief Accounting Officer Burkhart Erin sold 714.0 shares on Aug 13 ’24.
